3 results on '"Teixeira, Maurício"'
Search Results
2. Effects of Standardized Brazilian Green Propolis Extract (EPP-AF®) on Inflammation in Haemodialysis Patients: A Clinical Trial.
- Author
-
Duarte Silveira, Marcelo Augusto, Malta-Santos, Hayna, Rebouças-Silva, Jéssica, Teles, Flávio, Batista dos Santos Galvão, Erica, Pinto de Souza, Sergio, Dantas Dutra, Fábio Ricardo, Dantas Gomes, Marcel Miranda, Teixeira, Maurício Brito, Miranda Rebelo da Conceição, Luis Filipe, Nascimento, Carolina Sa, Vasques Nonaka, Carolina Kymie, Cezar, Rodrigo Silva, Pena Batista, Paulo Benigno, Berretta, Andresa Aparecida, Borges, Valeria M., and da Hora Passos, Rogerio
- Subjects
THERAPEUTIC use of plant extracts ,DRUG efficacy ,INTERLEUKINS ,C-reactive protein ,CYTOKINES ,CLINICAL trials ,INFLAMMATION ,ANTI-inflammatory agents ,IMMUNOMODULATORS ,TREATMENT effectiveness ,INTERFERONS ,TUMOR necrosis factors ,HEMODIALYSIS ,PATIENT safety - Abstract
Background. Patients on haemodialysis (HD) present a significant inflammatory status, which has a pronounced negative impact on their outcomes. Propolis is a natural resin with anti-inflammatory and immunomodulatory properties. We assessed the safety and impact of a standardized Brazilian green propolis extract (EPP-AF®) on the inflammatory status in patients under conventional HD. Methods. Patients were assigned to receive 200 mg/day of EPP-AF® for 4 weeks followed by 4 weeks without the drug, and changes in plasma levels of interleukins (ILs), interferon gamma (IFN-γ), tumour necrosis factor-alpha (TNF-α), and high-sensitivityc-reactive protein (HsCRP) were measured. A heatmap was used to illustrate trends in data variation. Results. In total, 37 patients were included in the final analysis. Patients presented an exacerbated inflammatory state at baseline. During EPP-AF® use, there was a significant reduction in IFN-γ (p = 0.005), IL-13 (p = 0.04 2), IL-17 (p = 0.039), IL-1ra (p = 0.008), IL-8 (p = 0.009), and TNF-α (p < 0.001) levels compared to baseline, and significant changes were found in Hs-CRP levels. The heatmap demonstrated a pattern of pronounced proinflammatory status at baseline, especially in patients with primary glomerulopathies, and a clear reduction in this pattern during the use of EPP-AF®. There was a tendency to maintain this reduction after suspension of EPP-AF®. No significant side effects were observed. Conclusion. Patients under haemodialysis presented a pronounced inflammatory status, and EPP-AF® was demonstrated to be safe and associated with a significant and maintained reduction in proinflammatory cytokines in this population. This trial is registered with Clinicaltrials.gov NCT04072341. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Efficacy of Brazilian green propolis (EPP-AF®) as an adjunct treatment for hospitalized COVID-19 patients: A randomized, controlled clinical trial.
- Author
-
Silveira, Marcelo Augusto Duarte, De Jong, David, Berretta, Andresa Aparecida, Galvão, Erica Batista dos Santos, Ribeiro, Juliana Caldas, Cerqueira-Silva, Thiago, Amorim, Thais Chaves, Conceição, Luis Filipe Miranda Rebelo da, Gomes, Marcel Miranda Dantas, Teixeira, Maurício Brito, Souza, Sergio Pinto de, Santos, Marcele Helena Celestino Alves dos, San Martin, Raissa Lanna Araújo, Silva, Márcio de Oliveira, Lírio, Monique, Moreno, Lis, Sampaio, Julio Cezar Miranda, Mendonça, Renata, Ultchak, Silviana Salles, and Amorim, Fabio Santos
- Subjects
- *
COVID-19 treatment , *PROPOLIS , *COVID-19 , *ACUTE kidney failure , *HOSPITAL patients - Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) promotes challenging immune and inflammatory phenomena. Though various therapeutic possibilities have been tested against coronavirus disease 2019 (COVID-19), the most adequate treatment has not yet been established. Propolis is a natural product with considerable evidence of immunoregulatory and anti-inflammatory activities, and experimental data point to potential against viral targets. We hypothesized that propolis can reduce the negative effects of COVID-19. In a randomized, controlled, open-label, single-center trial, hospitalized adult COVID-19 patients were treated with a standardized green propolis extract (EPP-AF®️) as an adjunct therapy. Patients were allocated to receive standard care plus an oral dose of 400 mg or 800 mg/day of green propolis for seven days, or standard care alone. Standard care included all necessary interventions, as determined by the attending physician. The primary end point was the time to clinical improvement, defined as the length of hospital stay or oxygen therapy dependency duration. Secondary outcomes included acute kidney injury and need for intensive care or vasoactive drugs. Patients were followed for 28 days after admission. We enrolled 124 patients; 40 were assigned to EPP-AF®️ 400 mg/day, 42 to EPP-AF®️ 800 mg/day, and 42 to the control group. The length of hospital stay post-intervention was shorter in both propolis groups than in the control group; lower dose, median 7 days versus 12 days (95% confidence interval [CI] −6.23 to −0.07; p = 0.049) and higher dose, median 6 days versus 12 days (95% CI −7.00 to −1.09; p = 0.009). Propolis did not significantly affect the need for oxygen supplementation. In the high dose propolis group, there was a lower rate of acute kidney injury than in the controls (4.8 vs 23.8%), (odds ratio [OR] 0.18; 95% CI 0.03–0.84; p = 0.048). No patient had propolis treatment discontinued due to adverse events. Addition of propolis to the standard care procedures resulted in clinical benefits for the hospitalized COVID-19 patients, especially evidenced by a reduction in the length of hospital stay. Consequently, we conclude that propolis can reduce the impact of COVID-19. [Display omitted] • 124 hospitalized COVID-19 patients were randomized into three groups. • 0, 400 or 800 mg/day of a standardized Brazilian green propolis was provided. • Adjunct treatment with propolis anticipated hospital release by five to six days. • The 800 mg propolis dose reduced kidney damage associated with COVID-19. • Propolis was safe and effective as an adjunct treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.